Papilloma

The Worldwide HPV Testing and Pap Test Industry is Projected to Reach $9.2 Billion by 2027: Rising HPV Cases and Subsequent Increase in Cervical Cancer Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Infectious Diseases, Health, Oncology, Medical Devices, HPV, Laboratory, Papilloma, Vaginal cancer, Pap test, Cervical cancer, Growth, PAP, Cancer, USD, Vaccine, Hospital

The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co- Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period
    The HPV testing and Pap test market is segmented into HPV testing and Pap test.
  • In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market.
  • The cervical cancer screening segment accounted for the highest growth rate in the HPV testing and Pap test market, by application, during the forecast period
    The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening.

The Worldwide Cytology and HPV Testing Industry is Expected to Reach $14.9 Billion by 2027: Increasing Awareness of Cervical Cancer Screening Programs Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Infectious Diseases, Pharmaceutical, Health, Ansoff Matrix, Clifton Springs Hospital & Clinic, SWOT, Papilloma, Product type, USD, Hospital, Porter's five forces analysis, Risk, Growth, Impact, Cervical cancer, Investment, Laboratory, Vaginal cancer, Competitive analysis, COVID-19, PCR, Emotion, HPV, Observation, Market development, Instrument, Geography, Nursing care plan, Vaccine, Marketing, Risk management, Retail, Pharmaceutical industry, Application, Immunoassay

The report presents a detailed Ansoff matrix analysis for the Global Cytology and HPV Testing Market.

Key Points: 
  • The report presents a detailed Ansoff matrix analysis for the Global Cytology and HPV Testing Market.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
  • The report offers a comprehensive evaluation of the Global Cytology and HPV Testing Market.
  • By Product Type, the market is classified into PCR, Immunodiagnostics, and Other
    By Application, the market is classified into Cervical Cancer Screening and Vaginal Cancer Screening.

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer

Retrieved on: 
Tuesday, December 6, 2022
MSD, Papilloma, ASA, Head, Merck, Oslo Stock Exchange, OSE, Adaptation, Nature, Safety, Cancer, Merck Sharp & Dohme Federal Credit Union, HPV, Regeneron Pharmaceuticals, Pembrolizumab, ORR, B cell, Hoffmann-La Roche, Infection, Cervical cancer, Therapy, Merck & Co., Risk, Uncertainty, COVID-19, Patient, Pharmaceutical industry, Genentech

The candidate has reported interim data from a Phase 2 trial in heavily pre-treated cervical cancer patients (NCT04405349).

Key Points: 
  • The candidate has reported interim data from a Phase 2 trial in heavily pre-treated cervical cancer patients (NCT04405349).
  • The analysis demonstrated a favorable safety profile, with responses observed in both PD-L1 positive and negative patients (ORR 27% and 17%, respectively).
  • The vaccine-induced significant HPV16-specific T cell responses were associated with clinical responses.
  • Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases.

Global HPV Testing and Pap Test Market Report 2022 to 2027: Innovative Improvements in HPV Tests Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
General Health, Health, Oncology, PAP, Laboratory, Cancer, Vaginal cancer, HPV, Pap test, USD, Growth, Cervical cancer, Papilloma, Vaccine, Hospital

The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co-Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co-Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period
    The HPV testing and Pap test market is segmented into HPV testing and Pap test.
  • In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market.
  • In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market.

Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, Cervical cancer, Adaptation, OSE, B cell, Hoffmann-La Roche, Regeneron Pharmaceuticals, ASA, Therapy, Oslo Stock Exchange, Papilloma, Cancer, Infection, CET, HPV, Safety, Pharmaceutical industry, Genentech

A live and archived webcast of the presentation can be accessed in the Investors section of the Companys website: https://nykode.com/investors/financial-reports-and-presentations .

Key Points: 
  • A live and archived webcast of the presentation can be accessed in the Investors section of the Companys website: https://nykode.com/investors/financial-reports-and-presentations .
  • Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases.
  • Nykode Therapeutics shares are traded on the Oslo Stock Exchange (OSE: NYKD).
  • Further information about Nykode Therapeutics may be found at http://www.nykode.com .

Nykode Therapeutics to present at two upcoming investor conferences in November

Retrieved on: 
Monday, November 7, 2022
Papilloma, GLOBE, Investor, B cell, Safety, Adaptation, COVID-19, Therapy, Cervical cancer, HPV, Jefferies, OSE, Regeneron Pharmaceuticals, Cancer, ASA, Infection, Hoffmann-La Roche, Oslo Stock Exchange, Pharmaceutical industry, Genentech

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases.

Key Points: 
  • Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases.
  • Additionally, Nykode is conducting a Phase 1/2 trial with next-generation COVID-19 vaccine candidates.
  • Nykode Therapeutics shares are traded on the Oslo Stock Exchange (OSE: NYKD).
  • Further information about Nykode Therapeutics may be found at http://www.nykode.com .

Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm

Retrieved on: 
Thursday, October 27, 2022
IND, TLR, SEC, Company, University, Security (finance), U.S. Securities and Exchange Commission, TME, NASDAQ, Private Securities Litigation Reform Act, Publication, Cancer, Disease, Senior, Vaccine, Tumor microenvironment, MVA, Papilloma, Annual report, Oxford University Innovation, Nanoparticle, Drug discovery, Immune system, IV, HPV, Research, COVID-19, GLOBE, Autoimmunity, ChAdOx1, NIH, Jamil Khir Baharom, OUI, Monocyte, Macrophage, AstraZeneca, Cell, Vaccitech

OXFORD, United Kingdom, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as “VAX-INNATE.” The results show that intravenous (IV) administration of SNAPvax not only primes and expands tumor-specific cytotoxic T cells that mediate tumor killing but also reverses suppression in the tumor microenvironment associated with significantly improved tumor regression.

Key Points: 
  • The results show that intravenous (IV) administration of SNAPvax not only primes and expands tumor-specific cytotoxic T cells that mediate tumor killing but also reverses suppression in the tumor microenvironment associated with significantly improved tumor regression.
  • The research evaluated SNAPvax co-delivering tumor antigens and a powerful Toll-like receptor (TLR)-7/8 adjuvant by two different routes (IV or subcutaneous) in tumor-bearing mice.
  • The aforementioned research was first published online in Cell and can be accessed at the link in the citation below.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit

Retrieved on: 
Wednesday, October 26, 2022
DNA, Safety, Cancer, VB, Risk, Squamous cell carcinoma, Immunotherapy, Fatigue, Papilloma, Patient, Uncertainty, Technology, Diarrhea, ELISpot, B cell, Protein, Cervical cancer, Adaptation, Oslo Stock Exchange, Partnership, Immune system, Toxicity, Nature, HPV, GLOBE, NSCLC, APC, COVID-19, Infection, CD8, Hoffmann-La Roche, Therapy, OSE, Roche, Head, Neck, Regeneron Pharmaceuticals, ASA, Vaccine, Pharmaceutical industry, Genentech

The data will be presented today at the Neoantigen-Based Therapies Summit in Boston, Massachusetts.

Key Points: 
  • The data will be presented today at the Neoantigen-Based Therapies Summit in Boston, Massachusetts.
  • The data continue to substantiate our differentiated platform technology and support its huge potential within individualized cancer treatments.
  • Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases.
  • A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Oncology, LinkedIn, Papilloma, CLIA, College of American Pathologists, Risk, Mayo Clinic, Disease, American Society for Radiation Oncology, Head, Radiation, DART, TTMV, List of pathologists, Society, Patient, Biotechnology, Twitter, Annual general meeting, Cancer, III, DRS, MRD, Radiation therapy, ASTRO, Progression-free survival, Toxicity, CEO, College, Recurrence, HPV, OPSCC, DNA, Medical imaging, Pharmaceutical industry, Vaccine, Raoul de Navery

radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.

Key Points: 
  • radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.
  • The presence of MRD, both in the post-operative setting and at 3 months post-treatment, was significantly associated with shorter progression-free survival.
  • Results from the MC1675 trial were initially presented at the ASTRO 2021 annual meeting and follow-up is ongoing.
  • More information on Naveris and NavDx can be found at booth #2348, or look for highlights from #ASTRO22 Twitter and LinkedIn .

Global Cervical Dysplasia Market Report 2022: Technological Advancements in Screening Devices and Other Supporting Equipment Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, Papilloma, Ansoff Matrix, Risk, Observation, Therapy, Growth, SWOT, CAGR, Porter's five forces analysis, Investment, Geography, Academic institution, Industry, Research, Midsayap Diagnostic Center and Hospital, COVID-19, USD, Market development, Medical device, Pharmaceutical industry, Retail, Risk management, Colposcopy, Hospital, Biopsy

The Global Cervical Dysplasia Market is segmented based on Diagnostics Type, Treatment Type, End-users, and Geography.

Key Points: 
  • The Global Cervical Dysplasia Market is segmented based on Diagnostics Type, Treatment Type, End-users, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Cervical Dysplasia Market.
  • The Global Cervical Dysplasia Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Cervical Dysplasia Market.